Epilepsy: Psychiatric adverse effects of levetiracetam linked to genetic variation in dopamine signalling

Nature Reviews Neurology

Volumn 8, Issue 10, 2012, Pages 532-

  Wood, Heather ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; ETIRACETAM;

AGGRESSION; CLINICAL OBSERVATION; COMT GENE; DBH GENE; DOPAMINERGIC ACTIVITY; DRD2 GENE; DRUG EFFICACY; DRUG RETENTION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EVIDENCE BASED MEDICINE; GENE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; IMPULSIVENESS; IRRITABILITY; MENTAL DISEASE; NORADRENERGIC SYSTEM; NOTE; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SEROTONINERGIC SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPSE; TREATMENT PLANNING;

EID: 84872313238     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.184     Document Type: Note

References (1)

1. Helmstaedter, C. et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia doi:10.1111/j.1528-1167.2012.03603.x